Takeda Pharmaceutical Company Limited (TAK) is in a powerful position with both individual investors, who own 52% of the shares, and institutions, holding 48%. The companies low share price gives it a strong standing for investors seeking a bargain in pharma. In a noteworthy shift, Blackrock increased its stake in Takeda from 7.33% to 8.43%. The company reported strong Q3 results and outlook, indicating underestimation in terms of value.
Despite a stint of downward trending in the stock and the stepping down of CEO Christophe Weber, the company has a high dividend yield, though it presents potential pitfalls for U.S. investors. The dividend is expected to be ¥98.00. Takeda has declared a share repurchase plan for 2025 and updated progress on the same. The company has also announced a successful merger and subsidiary liquidation.
Takeda has also managed its debt responsibly despite the CEO change and a guidance raise. The company has recently gained an FDA approval and has plans for growth post-takeover. The company enters into an agreement with Vonoprazan tablets. The conclusion suggests potential for turnaround after a 6.19% drop in the past 4 weeks.
Takeda Pharmaceutical Stocks News Analytics from Mon, 09 Jan 2017 08:00:00 GMT to Sat, 19 Apr 2025 18:34:35 GMT -
Rating 4
- Innovation -3
- Information 7
- Rumor -2
